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Abstract 
CRISPR (clustered regularly interspaced short palindromic repeat) Cas9 systems is a 
novel technique for genome editing. In this thesis a start-up attempt using CRISPR 
Cas9 to induce site-specific mutations in Arabidopsis thaliana has been made. By this 
means, a guide RNA sequence targeting the specific site of interest has been created, 
amplified and ligated into a vector containing a pcoCas9-expression cassette. The 
work performed shows that the CRISPR Cas9 method is easy to set up. This thesis 
also evaluates the current EU legislation on genetically modified organisms and the 
impact of extending it to CRISPR Cas9 as well as seven other new plant breeding 
methods. Subjecting CRISPR Cas9 as well as the majority of the other discussed plant 
breeding techniques to the EU GMO legislation requires considerable amendment and 
reworking, as the condition of traceability cannot be met. To avoid making 
amendments for each new technique that may be developed in the future and to 
increase legal certainty in this field, this thesis proposes a rewriting of the EU GMO 
legislation into a technology neutral biosafety legislation. Rather than focusing on the 
plant breeding techniques used in a particular case, the legislators should define a 
GMO by the phenotypic criteria an organism displays after induced genetic 
modification. 
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Sammanfattning  
CRISPR (clustered regularly interspaced short palindromic repeat) Cas9 är en riktad 
mutationsteknik som under de senaste åren revolutionerat molekylärbiologin. 
Tekniken kan bland annat användas som en växtförädlingsteknik, men dess praktiska 
tillämpning inom EU är ännu oklar då Europeiska Kommissionen inte beslutat om 
CRISPR Cas9 samt sju andra växtförädlingstekniker kommer att omfattas av Eus 
nuvarande lagstiftning för genmodifierade organismer eller ej. Föreliggande arbete 
behandlar därav både CRISPR Cas9-tekniken som sådan och EUs lagstiftning för 
GMO.  
 
I den tekniska delen av detta examensarbete har ett arbete påbörjats för att inducera 
riktade mutationer i Arabidopsis thaliana. Konkret innebär det att en guidesekvens 
(sgRNA) skapats, amplifierats och ligerats in i en vektor som kan uttrycka Cas9 för 
växter. Den färdiga vektorn kan användas för vidare transformation in i 
Agrobacterium och sedan Arabidopsis. I den regulatoriska delen som behandlar EUs 
lagstiftning för GMO, har en litteraturgenomgång av rådande lagstiftning gjorts. 
Frågor om krav för att genomföra fältförsök med Arabidopsis muterade med CRISPR 
Cas9 har också skickats till Jordbruksverket för att få en bild av deras syn på tekniken 
i förhållande till dagens GMO-lagstiftning. I den regulatoriska delen finns ett fokus på 
spårbarhetslagen, då majoriteten av de nya växtförädlingsmetoderna som 
kommissionen arbetar med genererar produkter som varken kan detekteras eller med 
säkerhet särskiljas som GMO. Analysen av litteraturstudien har lett fram till slutsatsen 
att hela lagstiftningen bör ändras till att vara produktbaserad snarare än teknikbaserad. 
En sådan ändring gör att lagens syfte blir tydligare samt att det i framtiden blir lättare 
att handlägga och bedöma effekterna av nya tekniker.  
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Introduction 
Plant breeding comprise of many methods to improve crop yield and quality in order 
to meet the increasing demand for food, fibre and energy associated with a growing 
global population. The methods are also used to reduce environmental impact by 
allowing for lower consumption of pesticides, fertilisers and water.  
 
Classical plant breeding was first used in late 19th century, see e.g. Lehrman et al., 
(2014) and references within, and implemented Darwinian and Mendelian theories 
about selection and heritage of desired traits into elite plant varieties. By increasing 
mutation rates through use of X-rays or toxins, it was found possible to acquire new 
traits within plants. This technique of inducing random mutations came to be called 
mutagenesis. A century later, in early 1980, the first transgenic plant was created. 
This was the starting point for development of transgenic (GMO) methods to alter 
plant DNA. Recently, new genome editing techniques of site-directed mutagenesis 
have evolved. Two examples of such techniques are zinc finger nuclease (ZFN) as 
well as oligonucleotide directed mutagenesis (ODM) (Lusser et al., 2011). These two 
are growing in importance and are increasingly seen as very real alternatives to the 
more traditional plant breeding methods.  
 
In 2007, a working group was established by the European Commission to evaluate 
whether eight new techniques used to alter DNA, including ZFN and ODM, should 
fall within the EU GMO legislation (Directive 2001/18/EG and Regulation (EC) No 
1829/2003). Seven out of these eight techniques can be used to make alterations of 
plant DNA. A report was published by the group in 2011 but no conclusion was 
reached regarding the EU GMO legislation for the techniques in question (Lusser et 
al., 2011). The group did however state that “crops resulting from most of the 
techniques cannot be distinguished from conventionally bred crops and detection is 
therefore not possible”. 
 
While gene technology allowing for changes to be made at specific sites in the 
genome, mutagenic technologies instead generate a number of changes that are more 
or less random (Miraglia et al., 2004). According to the EU legislation, detection 
methods used to determine whether a specific crop is, in fact, a GMO, need to be 
available before that GMO crop is allowed on the market. Bearing this in mind, it is 
very understandable that mutagenesis as a plant breeding method is excluded from the 
EU GMO legislation (Directive 2001/18/EG) seeing as no such methods are available 
but any changes in the genome are indistinguishable from spontaneous mutations. As 
stated above, several of the new techniques, including ZFN and ODM allow for the 
induction of site-specific mutations, but the resulting crops are not distinguishable 
from crops bred using traditional mutagenic methods (Lusser et al., 2011). 
 
Since 2011 when the report by Lusser et al. was published, a new technique allowing 
for site-specific mutations, the CRISPR (clustered regularly interspaced short 
palindromic repeat) Cas9 method has been developed. This new technique has several 
advantages compared to other site-specific mutation methods such as ZFN, mostly 
thanks to the former being more easy to use and the ease of multiplexing i.e. genome 
editing at different loci simultaneously (Cong et al., 2013; Mali et al., 2013). Despite 
the continuous development of site-specific mutations techniques however, the 
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European Commission is still undecided as to whether all, some or any of the 
techniques should be subject to the traditional GMO legislation. 
 
This thesis will seek to explain and evaluate both the CRISPR Cas9 method itself as 
well as the impact of potential changes in the EU legislation whereby the method is 
considered to fall within the scope of GMO legislation. Part I, focusing on the 
method, is structured by way of a laboratory analysis where the CRISPR Cas9 method 
is set up to induced site-specific mutations in Arabidopsis thaliana in a continued 
work. Part II draws on the scientific conclusions from part I and offers an outline of 
the current EU legislation on GMO. The report also offers a discussion of the current 
legislation as well as of the feasibility and the impact of extending its reach to the 
CRISPR Cas9 method.  
 
 
Part I 
Background  
Plant breeding is, as previously stated, vital in order to improve crop plants and at the 
same time contribute to a sustainable food production. A new plant breeding 
technique allowing for site-directed mutation in the plant genome is the CRISPR Cas9 
method. Before explaining how the CRISPR Cas9 method can be used for prokaryote 
genome editing, the inheritable prokaryotic immune system has to be outlined as the 
CRISPR technique is based upon this natural phenomena (Jinek et al., 2012).  
 
CRISPR Cas – inheritable prokaryotic immune system 
Bacteria and archaea can resist viral and plasmid challenges by integrating short 
fragments of foreign nucleic acid into the genome at a specific locus consisting of 
short (20-50 bp) DNA repeat sequences (Sorek et al., 2013). These sequences are 
separated by spacer sequences of equal lengths; creating a repeat-spacer-repeat 
pattern that makes a CRISPR locus, figure 1a. There is a common repeat sequence 
within a CRISPR locus but the repeats can vary in both length and sequence when 
comparing two or more CRISPR loci, leaving a high diversity among CRISPR repeats 
(Kunin et al., 2007).  
 
A prokaryotic chromosome can contain one or more CRISPR loci (Godde & 
Bickerton, 2006). Within species that contain two or more CRISPR loci, there is a 
leader sequence rich in AT flanking one side of each locus (Jansen et al., 2002), 
figure 1a. The leader sequence consists of 300-500 base pairs (bp). In turn, CRISPR- 
associated sequence (Cas) genes have been found on either side of the CRISPR loci. 
There are several different types of Cas genes that codes for proteins within different 
families. However, the Cas1- and Cas2 genes are conserved in all genomes that 
contain CRISPR loci.  
 
There are three classified types of CRISPR Cas systems in prokaryotes and all three 
systems mediate immunity to invading viruses in a common three-stage process of 
adaptation, expression and interference (reviewed by Makarova et al., 2011). The 
difference between the systems is what other Cas genes, besides Cas1 and Cas2, that 
act mainly in the stages of expression and interference. No further comparison of the 
different CRISPR Cas systems will be made in this report. Instead, in order to 
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understand how the CRISPR method can be used as a genome engineering tool in 
eukaryotes, the stages of adaptation, expression and interference for the type II 
CRISPR Cas inheritable immune system in prokaryotes will be outlined below. 
 
Adaptation  
In the adaptation stage, short pieces of viral DNA are recognised, processed and 
integrated in the chromosomal CRISPR locus at the leader side (Barrangou et al., 
2007), figure 1b. The integrated sequences will bring out the function of a genetic 
memory and prevent the host from being infected by viruses with the same sequence. 
However, what sequence from the viral genome that is chosen to be integrated is not 
arbitrary. Instead, it has been found by analysing newly added spacer sequences that 
they contain a short motif downstream of the proto-spacer that is specific to the 
CRISPR Cas variant within the host (Mojica et al., 2009). Hence, the selection of 
spacer precursors (proto-spacers) from the invading DNA appears to be determined 
by the recognition of a proto-spacer-adjacent motif (PAM) with a sequence of 5’ -
NGG- 3’. How the PAM sequence is recognised remains still unknown. What is 
known is that the GG motif is required for proto-spacer plasmid DNA elimination by 
CRISPR Cas in bacterial cells (Jinek et al., 2012; Sapranauskas et al., 2011). 
However, the integration of the proto-spacer is followed by a duplication of a repeat, 
leaving a new spacer-repeat sequence within the CRISPR locus (Makarova et al., 
2006).   
 
 
 
 
Figure 1. a) A CRISPR locus in a prokaryote chromosome with the characteristic repeat(R)-spacer(Sx)-
repeat pattern. b) A prokaryote can recognise a PAM sequence within an invading virus/plasmid and 
integrate foreign nucleic acid from it, i.e. a proto-spacer (PS), in its CRISPR locus. The integration of 
the proto-spacer creates a new spacer (S0) and a repeat sequence (R). The figure is modified from van 
der Oost et al. (2009). 
 
 
Expression 
Following adaptation, a second stage called expression comes next in the CRISPR 
Cas mediated immunity (Makarova et al., 2011). In the leading sequence flanking the 
CRISPR locus, there is a promoter sequence that synthesises a primary transcript of 
the CRISPR locus (Brouns et al., 2008; Pul et al., 2010). The primary non-coding 
transcript that is synthesised is called a pre-CRISPR RNA (pre-crRNA) (Deltcheva et 
al., 2011). In turn, trans-activating CRISPR RNA (tracrRNA) that is complementary 
to the pre-crRNA and which pairs with its repeat sequence, cleaves the pre-crRNA 
into mature CRISPR RNAs (crRNAs) by the activities of endogenous RNase III and 
in the presence of a DNA endonuclease referred to as the Cas9 protein. 
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Interference 
During the third and final stage of interference, Cas9 protein cleaves the double-
stranded DNA (dsDNA) of the invading virus. The cleaving process starts by 
activation of the Cas9 which occurs through a base-pairing between tracrRNA and 
crRNA in the repeat sequence (Jinek et al., 2012). In turn, the Cas9 protein needs to 
be guided to the right location on the virus in order for the cleavage to be site-specific. 
This guidance occurs through a base pairing between the crRNA and the proto-spacer 
DNA at a location where the short PAM sequence, previously mentioned to also have 
a role in the adaptation stage, is present downstream of the target DNA, figure 2. Cas9 
is thereby both required for the maturation of crRNA in the expression stage and 
dsDNA cleavage in the interference stage. tracrRNA can in a similar way be 
described to have multiple functions of processing pre-crRNA by the enzyme 
RNaseIII in the expression stage (Deltcheva et al., 2011) and activating Cas9 
resulting in tracrRNA:crRNA-guided dsDNA cleavage (Jinek et al., 2012).  
 
When the Cas9 protein has been activated and guided to a specific position in the 
invading nucleic acid, the cleavage of the dsDNA will take place. At this stage, the 
two nuclease domains that the Cas9 contains i.e. RuvC-like and HNH nuclease 
domain (Makarova et al., 2006), play a major role. Sapranauskas et al., (2011) found 
that mutations in the RuvC and/or the HNH-motif abolish the ability of Cas9 to 
interfere with the plasmid DNA. The HNH-domain has thereby been considered 
essential in the DNA degradation step, as the HNH-domains are common components 
in nucleases that act on double-stranded DNA. It is today known that the HNH-
domain cleaves the complementary strand three bp upstream of the PAM of the 
invading nucleic acid (Jinek et al., 2012). The RuvC-domain cleaves the 
noncomplementary strand at one or several sites at a location of three to eight bp 
upstream of the PAM sequence (figure 2).  
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Figure 2. A model of the interference stage in the native prokaryotic CRISPR Cas defense system. 
Cas9 protein (grey) is activated by base pairing of crRNA (black) and tracrRNA (red). The Cas9 
protein is in turn guided to a specific cleavage site in the invading nucleic acid through base pairing of 
crRNA and the proto-spacer DNA in the presence of an adjacent PAM sequence (yellow). The HNH- 
and RuvC-domain in the Cas9 protein will cleave the dsDNA and hence destroy the invading nucleic 
acid. The figure is modified from Bortesi & Fischer (2015) and Jinek et al. (2012).  
 
 
The CRISPR Cas9 system as a genetic engineering tool 
The two-RNA structure that is formed between crRNA and tracrRNA in prokaryotes 
to guide the Cas9 protein to a specific location in the invading DNA, was in 2012 
found to guide Cas9 and induce an equal dsDNA cleavage in eukaryotes when 
engineered as a single RNA chimera (Jinek et al., 2012). At time for first design and 
trial, this structure was called a crRNA-tracrRNA chimera, but is today known as a 
single-guide RNA (sgRNA).  
 
A sgRNA contains a recognition sequence of 20 nucleotides to target the 
complementary DNA strand (Jinek et al., 2012), figure 3. Out of these 20 nucleotides, 
the ones located 5 to 12 positions adjacent to a U-shaped structure fusing the 3’ end of 
crRNA to the 5’ end of tracrRNA make the seed sequence. The seed sequence is 
particularly important for target recognition, but does not leave the remaining 
nucleotides within the target sequence as useless. On the contrary, the first nucleotide 
in the target sequence i.e. the nucleotide located 20 positions adjacent to the U-shaped 
structure, is important for transcription. The first nucleotide in the gRNA sequence 
should be a guanine (G) as the U6 RNA polymerase III prefers having a G as the first 
base in its promoter (Ran et al., 2013). The G-nucleotide and the U6 promoter are in 
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other words important for the expression of sgRNA. Finally, in order for the Cas9 
cleavage to take place, the target sequence has to be located adjacent to a PAM 
sequence of 5’ -NGG- 3’. Adding all together, the general sequence template to use 
when designing and building sgRNAs for Arabidopsis is 5’ -G N19 NGG- 3’ (Mali et 
al., 2013).  
 
A Cas9 protein programmed with a sgRNA induces a double strand break (DSB), but 
it is not the cleavage itself that generates the desired genetic mutation. Instead, the 
mutation is an outcome of the repair pathway of the broken DNA strand (Maresca et 
al., 2013; Rouet et al., 1994). DSBs can be repaired by homologous recombination 
(HR), also commonly discussed in terms of homologous directed repair (HDR), or 
non-homologous end joining (NHEJ) (Rouet et al., 1994). NHEJ is the major repair 
pathway (Ferreira & Cooper, 2004) and may results in random insertion or deletion of 
nucleotides when the two DNA ends are ligated together, as the joining of the DNA 
ends occurs irrespective of end sequences (Rouet et al., 1994). Knowing this, it is 
understandable that a DSB caused by CRISPR Cas9 and repaired by NHEJ will result 
in a mutation. This mutation will in turn be indistinguishable to any other mutation 
resulting from the repair of a DSB by NHEJ (Lusser et al., 2011).  
 
Natural cell repair of broken DNA through HR/HDR will, in contrast to NHEJ, result 
in a precise repair of the DNA (Rouet et al., 1994). This precision is a result of the 
cell’s use of homologous sequences around the DBS that work as templates in the 
repair process. When it comes to HR in the context of genetic modification, 
exogenously introduced repair templates in form of double-stranded DNA or a single-
stranded DNA oligonucleotide can be used to induce a targeted point mutation, 
targeted genomic deletion or targeted insertions of genetic elements that are 
associated with genomic deletions (Chen et al., 2011). The only requirement is that 
the exogenously introduced repair templates have homology sequences flanking the 
site of modification. Worth mentioning is that DNA templates with a transgene also 
can be inserted through NHEJ and not exclusively within the repair process of HR. 
Moreover, the HNH and RuvC nuclease domains within the Cas9 protein can be 
mutated to exploit new functions (Barrangou et al., 2007). This can, for instance, 
generate site-specific single-strand DNA breaks instead of double-strand breaks. 
However, using CRISPR Cas9 to induce DSBs that are repaired by NHEJ without the 
presence of a repair template is the technique that is relevant for this thesis.    
 
Since the first discovery of the possibility to use a Cas9 protein programmed with a 
sgRNA to induce site-specific DBSs, it has been found that multiple guide RNAs 
(gRNAs) with different sequences can be introduced into a single CRISPR array 
(Cong et al., 2013; Mali et al., 2013). Using several different gRNAs allows for 
simultaneous genome editing at different sites. The use of the CRISPR Cas9 method 
can thereby be described as a technique which is easy to use, inexpensive compared to 
other methods and as a technique that has a wide range of purposes (Bortesi & 
Fischer, 2015). It is therefore understandable why research groups across the world 
are working with the CRISPR Cas9 method, especially when knowing that CRISPR 
Cas9 can induce site-specific, endogenous, genetic changes in a wide range of species 
including human (Jinek et al., 2013), mouse (Cong et al., 2013), zebrafish (Hwang et 
al., 2013) and plants (Feng et al., 2013; Li et al., 2012; Nekrasov et al., 2013; Shan et 
al., 2013; Xie et al., 2014).  
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Figure 3. A model of the CRISPR Cas9 system for eukaryotic genome editing. A Cas9 protein (grey) is 
programmed with a sgRNA (green). The sgRNA target sequence, binding to the proto-spacer, consists 
of 20 nucleotides; 5-12 nucleotides out of these make the seed sequence (orange) that is particularly 
important for target recognition. The presence of a PAM sequence of 5’ -NGG- 3’ (yellow) is required 
for Cas9 cleavage of the dsDNA by the nucleases RuvC and HNH. The figure is modified from Bortesi 
& Fischer (2015) and Jinek et al. (2012).  
 
 
Interrupting stamen development in Arabidopsis by use of CRISPR Cas9 
The structure of the mature flower of Arabidopsis thaliana is typical for Brassicaceae 
i.e. an important family of flowering plants (Angiosperms). It has a sterile perianth 
consisting of four sepals and four petals that surrounds the reproductive organs 
(Smyth et al., 1990). The reproductive organ does in turn consist of six stamens and 
two fused carpels that build up the pistil.  
 
The development process of the mature flower of Arabidopsis can be divided into 14 
distinct stages from floral initiation to anthesis (Smyth et al., 1990). The process starts 
with the initiation of a floral buttress on the apical meristem and ends with the 
opening of a one millimetre long bud. Total time taken for all 14 stages to proceed is 
13.25 days and approximately 1.9 buds are being initiated on average each day. 
Looking specifically at stamen development, it starts in floral stage 5 with the 
appearance of stamen primordia (Smyth et al., 1990). In later stages, the primordia 
will bulge out and form a filament with anthers on top. Within an anther, four pollen 
sacks surrounded by a distinct cell layer called the tapetum layer will develop. The 
tapetum layer functions as a nurturing cell-layer for the developing pollen grains, 
which, in turn, are released during anthesis.  
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Development of stamen primordia specification depends on the interaction of a 
number of genes as well as on a correlated action of the mitochondrion (Carlsson et 
al., 2008). Alves-Ferreira et al., (2007) have shown that genes located in the tapetum 
are active during stamen development. The functions of individual genes are although 
unknown. A way to study gene function, including function of genes being closely 
related to each other, is to induce point mutation(s) within the protein-coding region 
of the genes of interest, e.g. through using the CRISPR Cas9 method. In case of genes 
with putative functions during tapetum development (figure 4) CRISPR Cas9 can be 
used to induce individual gene knockouts so as to interrupt stamen development and 
thereby get a deeper understanding of genes regulating male fertility.   
 
 
 
 
Figure 4. Genes located on chromosome 1 in Arabidopsis and implicated in stamen development. Here 
named A120, A130, A132, A135, A140, A150 and A160. 
 
 
Male sterility in hybrid seed production 
Hybrid seed production involves cross-pollination of two homozygote parental lines. 
This will generate a heterozygote progeny that displays a superior performance called 
heterosis or hybrid vigour. Heterosis in the progeny is exhibited as better plant growth 
and a higher biomass yield compared to the parental lines and/or conventional lines 
(Birchler et al., 2003).  
 
In order for cross-pollination to occur, self-pollination of the female plant has to be 
prevented. This can be accomplished through manual removal of anthers or use of 
chemicals. In fact, it was found already in 1954 that subjecting plants to α-
naphthaleneacetic acid resulted in exclusive production of pistillate flowers (Wittwer 
& Hillyer, 1954). However, chemicals may cause damage to the rest of the plant and 
manual removal of anthers is time- and labour intensive (Perez-Prat & van Lookeren 
Campagne, 2002). It may be possible to manually remove anthers in monoecious 
plants such as corn, where the male and female flowers are located at separate parts of 
the plant. This is possible but difficult in plants with bisexual flowers, e.g. oilseed 
rape, as the anthers then have to be removed from each flower.  
 
Male-sterility of a female plant, as an outcome of an induced genetic defect to nuclear 
or cytoplasmic genes, is to be preferred before manual emasculation or use of 
chemicals (Horner & Palmer, 1995; Perez-Prat & van Lookeren Campagne, 2002). 
Causing gene defects within hybrid seed production does although require knowledge 
about genes being involved in stamen development; highlighting the value of 
inducing site-directed mutations discussed in previous section. Making such trials will 
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give a deeper understanding of how male-sterility can be induced and may thereby 
enhance hybrid seed production.   
 
Aim/hypothesis 
The aim of part I is to make a start-up attempt for using CRISPR Cas9 to induce site-
specific mutations in Arabidopsis thaliana. To be more precise, the aim is to 
transform a binary vector containing a pcoCas9-expression cassette for plant 
expression of Cas9 and a sgRNA sequence targeting gene A120 (figure 4) into E. coli 
(DH5α). Whether the aim is fulfilled or not will be checked by DNA sequencing of a 
colony from the transformed E. coli. The aim of part I is also to design sgRNAs to 
target the remaining genes that are illustrated in figure 4. These gRNAs should be 
possible to use in CRISPR arrays targeting a single site within Arabidopsis, but also 
possible to use in CRISPR arrays that allowing for simultaneous editing at several 
sites.  
 
A satisfying result of this aim will make the foundation of a greater research project in 
which the created binary vector (containing pcoCas9-expression cassette and sgRNA 
targeting gene A120) can be transformed into Agrobacterium. A conformation of the 
usability of this method will also allow creation of additional vectors containing the 
remaining gRNAs that have been designed. However, once having a vector containing 
desired gRNA sequence(s) cloned into Agrobacterium, it can be transformed into 
Arabidopsis. Plants of the T0-generation will be heterozygote with regards to the 
CRISPR Cas9 transgene, whereby homozygote T1-plants will be selected and further 
used, see appendix C for more information. By making Agrobacterium transformation 
into Arabidopsis, disruption/knockout of genes will be made as a result of NHEJ of 
induced CRISPR Cas9 DSB(s). This will in turn allow testing of the hypothesis that 
knockout of abovementioned genes reduce male fertility.    
 
 
Materials and Method 
Vector plasmids 
Two vector plasmids have been used. Both vectors were ordered from Addgene.  
 
1. pUC119-gRNA (Addgene plasmid # 52255)  
 
The pUC119-gRNA vector contains an Arabidopsis U6 promoter that targets the 
AtPDS3 gene, target site 1, to drive sgRNA expression (Addgene, 2015b). 
 
2. pFGC-pcoCas9 (Addgene plasmid # 52256)  
 
pFGC-pcoCas9 is a binary vector that contains a pcoCas9-cassette for plant 
expression of Cas9 (figure 5). It also contains a multiple cloning site for insertion of 
guide RNA as well as two selection markers. The kanamycin resistant gene is used for 
bacteria selection at lab while the BAR-gene, a glufosinate resistance gene, is used for 
selection in plants (useful for confirming that the CRISPR Cas9 transgene is absent in 
chosen progenies of the T1-generation, appendix C).   
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Figure 5. The binary vector pFGC-pcoCas9 (Addgene plasmid # 52256). The figure is modified from 
(Addgene, 2015a).  
 
 
Mini- and Maxiprep samples of vectors plasmids 
The vector plasmids arrived as stab cultures (pFGC-pcoCas9/DH5α and pUC119-
gRNA/DH5α). Bacteria containing the vectors were re-streaked on lysogeny broth 
(LB)-agar plates. Vector pUC119-gRNA/DH5α was grown on a LBampicillin-plate and 
vector pFGC-pcoCas9/DH5α on a LBkanamycin-plate. Single colonies were picked from 
these plates and incubated overnight in liquid LB with corresponding antibiotics 
added. In turn, two Miniprep samples of vector pUC119-gRNA/DH5α as well as three 
Miniprep samples of vector pFGC-pcoCas9/DH5α were made. User manual was 
followed (Life Technologies).  
 
An additional Maxiprep sample of vector pFGC-pcoCas9/DH5α was made 
approximately two months after making the Minipreps. User manual was followed 
(Life Technologies).  
 
Finding CRISPR sites (sgRNA sequences)  
To find CRISPR sites i.e. gRNA sequences targeting genes A120, A130, A132, A135, 
A140, A150 and A160, the programme Geneous 8.0.5 was used. For each gene, full-
length cDNA and full-length genomic information for Arabidopsis were downloaded 
from the website arabidopsis.org. A translation of the cDNA was then performed in 
the Geneous programme. Translation frames were chosen to avoid stop codons within 
the translated sequences.  
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When having a translated cDNA sequence for a gene, the cloning function in 
Geneous, which includes an option of finding CRISPR sites, was used. Target 
sequence was set at G(N19). PAM sequence used was NGG. When searching for 
endogenous CRISPR sites with these target- and PAM sequences, a number of results 
were shown. CRISPR sites located in exons, in the beginning of the protein-coding 
region of genes and with a low off-target frequency were chosen and further used in 
creation of polymerase chain reaction (PCR) primers.  
 
Designing PCR primers  
Primers to assemble gRNA 
Sets of four PCR primers, two forward and two reverse, were designed in Geneous 
8.0.5 for each gene. These were designed to work with a PCR method published by Li 
et al. (2013). Out of the four primers in each set, one forward and one reverse primer 
(U6_F2 and U6_R1) were gene specific i.e. based on the CRISPR site found. The 
other forward and reverse primers included in each set, U6_F1 and U6_R2, were 
designed to work for all genes. Sequences for these non-specific primers were built 
with regards to the multiple cloning site of vector pFGC-pcoCas9. 
 
Two different types of the non-specific forward and reverse primers were designed in 
order to have the option of creating CRISPR arrays that target a single genomic site as 
well as arrays that target multiple sites. This is further explained in the section of 
ligation, method A. Sequence templates used in the primer designing process are 
listed in table 1 and adapted from Li et al. (2013).  
 
Table 1. Naming of PCR primers and templates used in sequence building.  
 
* The last three numbers in targeted gene, e.g. 140 in gene A140, complete primer name. For some 
genes, more than one primer was design as two CRISPR sites were chosen. In cases of multiple 
primers targeting the same gene, the tree last numbers in gene name are following by a letter, e.g. 
U6_F2_120a.  
 
Primers to use with NEBuilder Hifi DNA Assembly Cloning Kit  
When having a gRNA expression cassette, it can be run in an additional PCR reaction 
to work with the NEBuilder Hifi DNA Assembly Cloning Kit (ligation). As this 
method was tried, further explained in the section ‘ligation method B’, two additional 
primers had to be designed. These have been named NEB_U6_F1 type 1 and 
NEB_U6_R2 type 1 and modified from primer U6_F1 type 1 and U6_R2 type 1 
respectively. NEB_U6_F1 type 1 and NEB_U6_R2 type 1 were ordered from 
Invitrogen (Life Technologies). 
 
Primer name Templates used in sequence building (5’ to 3’) 
U6_F1 type 1 NNN + EcoRI + AGAAATCTCAAAATTCCG 
U6_F1 type 2 NNN + XbaI + AGAAATCTCAAAATTCCG 
U6_F2 * The 5’-most N23 of a gRNA target site + 
GTTTTAGAGCTAGAAATAGC 
U6_R1 * Reverse complement of the 5’-most N23 of a gRNA target site + 
AATCACTACTTCGTCTCT 
U6_R2 type 1 NNN + XbaI+ TAATGCCAACTTTGTACA 
U6_R2 type 2 NNN + AsiSI+ TAATGCCAACTTTGTACA 
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The NEBuilder Hifi DNA Assembly Cloning Kit can also, apart from being used for 
ligation of a single gRNA expression cassette, be used to assemble up to five DNA 
fragments in a single linear vector (New England BioLabs, 2015). The only 
requirement is that the DNA fragments, PCR-amplified, have overlapping ends of 15-
30 bp. This method is further described in the section ‘ligation method B’, but a 
description of primer design follows below.   
 
For the purpose of making CRISPR arrays simultaneously targeting five sites, several 
new primers were created. The first primers were created in the Geneous programme 
and named U6_F1 NEB_x and U6_R2 NEB_x. U6_F1 NEB_x were based on the 
common sequence in U6_F1 type 1 and U6_F1 type 2, i.e. 
AGAAATCTCAAAATTCCG and U6_R2 NEB_x on the common sequence in 
U6_R2 type 1 and U6_R2 type 2, i.e. TAATGCCAACTTTGTACA. In addition to 
these sequences, individual sequences of 20 nucleotides were added to make the 
complete primer sequences, see appendix A table 1. These primers will be used in 
five separate PCR reactions with the gRNA expression cassettes that should be ligated 
together (further explained in the section ‘ligation method B’).  
 
In order to make remaining primers to use for multiple assemble of gRNA, the 
programme NEBuilder Assembly Tool 1.8.0 was used. A FASTA sequence of vector 
pFGC-pcoCas9 was uploaded in the NEBuilder Assembly Tool programme. The 
vector was virtually cut by EcoRI and XbaI. In turn, sequences for gRNA expression 
cassettes flanked by primer sequences U6_F1 NEB_x and U6_R2 NEB_x were 
uploaded. By using preferences set to a minimum primer length of 18 bp and a 
minimum overlap of 15 bp, primer sequences that will overlap the gRNA expression 
cassettes were created. This will enhance the ligation. All primers were ordered from 
Invitrogen (Life Technologies). 
 
PCR  
Assembly of gRNA (gRNA expression cassette) 
The vector pUC119-gRNA was used as a PCR template to assemble individual 
expression cassettes including specific gRNA sequences for all genes. The complete 
assembly of a single gRNA expression cassette required three PCR reactions; round 1, 
round 2.1 and round 2.2. All rounds, i.e. the three PCR reactions, are further 
explained below in a general approach with respect to primers used. The PCR 
reactions and the assembly of a gRNA expression cassette are graphically illustrated 
in figure 8 on next page to help the reader understand the PCR reactions described. 
Details of which primers that were used to assemble gRNA expression cassettes for 
each gene are listed in table 2.  
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Figure 8. Illustration of how primers U6_F1, U6_R1, U6_F2 and U6_R2 assemble a gRNA (CRISPR site) in PCR reactions 1, 2.1 and 2.2. The whole sequence region i.e. 
primers as well as the assembled gRNA make the gRNA expression cassette. This gRNA expression cassette can, due to the flanking restriction sites in primers U6_F1 and 
U6_R2 (table 1), be ligated to vector pFGC-pcoCas9. This is further explained on next page. A part of the sequence in between U6_F1 and U6_R1 is truncated because of 
space constraints.  
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Phusion High-Fidelity DNA Polymerase was used in all PCR reactions and the user manual 
was followed when making the mastermix.   
 
PCR Round 1 
Two separate reactions are included in the first PCR round. In the first reaction, the left part of 
the gRNA expression cassette will be generated while the right part of the expression cassette 
is generated in the second reaction, figure 8. The defining gRNA sequence will be amplified 
in both reactions as its sequence is included in primer U6_R1 and U6_F2.  
 
Following two reactions were set up: 
 
18 μl mastermix + 0.5 μl 10μM U6_F1+ 0.5 μl 10μM U6_R1 + 1 μl pUC119-gRNA 
 
18 μl mastermix + 0.5 μl 10μM U6_F2+ 0.5 μl 10μM U6_R2 + 1 μl pUC119-gRNA 
 
PCR round 1 was brought out according to protocol in figure 6 below. 
 
98°C 98°C    72°C 72°C   
30’’ 10’’  62°C  30’’ 10’  12°C 
   20’’     ∞ 
     × 35    
Figure 6. Illustration of conditions in PCR round 1. The figure shows conditions for initial denaturation, the 35 
cycles of denaturation, annealing and extension as well as the final extension. Single apostrophe (’) represent 
minutes and double apostrophes (’’) represent seconds.  
 
PCR products from round 1 were purified by use of a PCR purification kit (Life 
Technologies) before used in PCR round 2.1. Concentration measurement of the purified 
products was made as well.  
 
PCR Round 2.1 
PCR round 2.1 joins the right and the left part of the gRNA expression cassette together so as 
to get a complete cassette.   
 
Purified PCR products from round 1 was used in following reaction:  
 
5 μl (U6_F1+U6_R1) + 5 μl (U6_F2+U6_R2) + 10 μl mastermix 
 
 
PCR round 2.1 was brought out according to protocol in figure 7 below.  
   
98°C 98°C    72°C   
3’ 30’’  62°C  10’’  12°C 
   30’’    ∞ 
     × 1   
Figure 7. Illustration of conditions in PCR round 2.1. The figure shows conditions for initial denaturation, the 
single cycles of denaturation, annealing and extension as well as the final extension. Single apostrophe (’) 
represent minutes and double apostrophes (’’) represent seconds.  
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PCR Round 2.2 
In the final PCR round, the complete gRNA expression cassette generated in PCR round 2.1, 
will be amplified so as to get a high concentration to use for ligation.  
 
The following reaction was set up with products from PCR round 2.1:  
 
17 μl mastermix + 0.5 μl U6_F1 + 0.5 μl U6_R2 + 2 μl product from PCR round 2.1. 
  
Protocol run was the same as for PCR round 1 shown in figure 6.   
 
The final PCR product from round 2.2 was purified using a PCR purification kit (Life 
Technologies). The purified product was in turn electrophoresed on 1% agarose gel (TBE-
buffer) with a few drops of ethidium bromide (EtBr) added. By doing this, the product size 
could be checked.  
 
A PCR product from round 2.2 will further be referred to as a gRNA expression cassette, 
highlighting the presence of assembled gRNA as well as the region in between forward 
primer U6_F1 as well as reverse primer U6_R2 within the product. For a graphical 
illustration, see figure 8.  
 
Table 2. Primers used in PCR reactions to assemble gRNA sequences.  
Gene (gRNA target) Primers used in PCR reaction 
A120 U6_F1 type 1 
U6_F2 120a or U6_F2 120b 
U6_R1 120a or U6_R1 120b 
U6_R2 type 1 
A130 U6_F1 type 2 
U6_F2 130a or U6_F2 130b 
U6_R1 130a or U6_R1 130b 
U6_R2 type 2 
A132 U6_F1 type 1 
U6_F2 132a or U6_F2 132b 
U6_R1 132a or U6_R1 132b 
U6_R2 type 1 
A135 U6_F1 type 2 
U6_F2 135 
U6_R1 135 
U6_R2 type 2 
A140 U6_F1 type 1 
U6_F2 140 
U6_R1 140 
U6_R2 type 1 
A150 U6_F1 type 2 
U6_F2 150 
U6_R1 150 
U6_R2 type 2 
A160 U6_F1 type 2 
U6_F2 150 
U6_R1 150 
U6_R2 type 2 
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Ligation 
Two different ligation methods, A and B, were used in order to ligate the gRNA expression 
cassette into vector pFGC-pcoCas9/DH5α. gRNAs targeting all seven abovementioned genes 
were assembled through PCR reactions. As a proof of concept, the gRNA expression cassette 
containing assembled gRNA targeting gene A120 (made from primers U6_F1_type 1, 
U6_F2_120a, U6_R1_120a and U6_R2_type 1) was from this point further used. This sample 
will be referred to as gRNA120a expression cassette.  
 
Ligation method A – T4 ligase 
Preceding ligation, the gRNA120a expression cassette and vector pFGC-pcoCas9 (MiniPrep 
sample with a concentration of 122.4 ng/μl) were set up in separate fast digest restriction 
enzyme reactions. Enzymes used in the reactions were EcoRI and XbaI (Life Technologies). 
User manual was followed. The optional step of heat inactivation was not performed. Instead, 
direct following enzyme digestion, both samples were electrophoresed on 1% EtBr agarose 
gel. Clear bands shown were cut from the gel and purified by use of a gel purification kit (Life 
Technologies).  
 
Concentration measurement for the two gel-purified samples was made post purification. In 
turn, these were ligated together using T4 ligase (Life Technologies). User manual was 
followed for making reaction buffer. The ligation reaction were brought out at 16°C for 
approximately 16 hours.  
 
Ligation method A to insert two gRNA expression cassettes in a single vector  
As mentioned in the section of ‘primers designed to assemble gRNA’, two different types of 
the non-specific forward and reverse primers, U6_F1 and U6_R2 were created in order to 
allow insertion of two gRNA expression cassettes in a single vector. Trials with multiple 
insertions of gRNA sequences were not performed in this experiment. However, following 
method can be used in future to insert two gRNA expression cassettes into a single vector for 
Cas9 expression.  
 
1. Make a complete ligation reaction (described above for gRNA120a) for any gRNA 
expression cassette made from primers U6_F1_type 1 and U6_R2 type 1 (table 2).  
2. Set up a fast digest restriction enzyme reaction in which the ligated sample is digested 
by enzymes XbaI and AsiSI. An additional enzyme digest reaction would be set up as 
well in which any gRNA expression cassette made from primers U6_F1_type 2 and 
U6_R2_type 2 reacts with XbaI and AsiSI.  
3. Make a T4 ligation (described above). In this reaction, the gRNA expression cassette 
digested by XbaI and AsiSI will be ligated to the end of the first introduced gRNA 
expression cassette as well as to the linear vector. This will generate a circular 
structure.  
 
Ligation method B - NEBuilder Hifi DNA Assembly Cloning Kit 
Setting up a PCR reaction with the gRNA120a expression cassette, started ligation method B. 
The reaction was as follows:  
 
18 μl mastermix + 0.5 μl 10μM NEB_U6_F1 type 1 + 0.5 μl 10μM NEB_U6_R2 type 1 + 1 μl gRNA120a 
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The PCR product was electrophoresed on 1% EtBr agarose gel to check the product length 
before moving on to next step.   
 
Next step was a fast digest restriction enzyme reaction for vector pFGC-pcoCas9 (MaxiPrep 
sample with a concentration of 2 μg/μl). Enzymes used in the reaction were EcoRI and XbaI 
(Life Technologies). The reaction proceeded during 20 minutes before it was heat inactivated. 
The sample was in turn electrophoresed on 1% EtBr agarose gel to check that the reaction had 
generated a clear band indicating a successfully digestion. The sample was in turn gel-purified 
(Life Technologies).  
 
Following the gel-purification, the NEBuilder Hifi DNA cloning was performed. The 
assembly protocol was followed for setting up the reaction. Products used in the reaction, 
apart from the assembly mix, were 2μl of digested vector pFGC-pcoCas9 as well as 0,5μl 
gRNA120a (product from additional PCR with NEB primers). The assembly reaction 
proceeded for 60 minutes at 50°C.  
 
Ligation method B to insert five gRNA expression cassettes in a single vector 
The NEBuilder Hifi DNA Assembly Cloning Kit can be used for simultaneous insertion of 
several sequences into a linear vector as previously mentioned. Primers to make such reaction 
have been created but no trial has been made. However, following can be done in future to 
insert five gRNA expression cassettes into vector pFGC-pcoCas9: 
 
1. Set up a fast digest reaction for vector pFGC-pcoCas9 with restriction enzymes EcoRI 
and XbaI.  
2. NEB-PCR reaction 1: Set up a PCR reaction with the gRNA expression cassettes and 
primers listed in NEB-PCR reaction 1 in table 3.  
3. NEB-PCR reaction 2: Use PCR products from NEB-PCR reaction 1 and make 
additional PCR reactions with primers listed in NEB-PCR reaction 2 in table 3. 
4. Following the gel-purification of vector pFGC-pcoCas9, the NEBuilder Hifi DNA 
cloning can be performed. Use 2μl of digested vector pFGC-pcoCas9 as well as 0.5 μl 
of each product from NEB-PCR reaction 2 for an assembly reaction. The assembly 
reaction should proceeded for 60 minutes at 50°C. 
 
Table 3. Additional PCR reactions for assembled gRNA expression cassettes in order to work 
with NEBuilder Hifi DNA cloning.  
gRNA expression cassette for 
associated genes:  
Primers used in NEB-PCR 
reaction 1 
Primers used in NEB-PCR 
reaction 2 
A120 NEB_U6_F1 type 1 
U6_R2_NEB_A 
NEB_U6_F1 type 1 
gRNA_A_rev 
A130 U6_F1 NEB_B 
U6_R2_NEB_B 
gRNA_B_fwd 
gRNA_B_rev 
A132 U6_F1 NEB_C 
U6_R2_NEB_C 
gRNA_C_fwd 
gRNA_C_rev 
A135 U6_F1 NEB_D 
U6_R2_NEB_D 
gRNA_D_fwd 
gRNA_D_rev 
A150 U6_F1 NEB_E 
NEB_U6_R2 type 1 
gRNA_E_fwd 
NEB_U6_R2 type 1 
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Transformation of ligated products into chemically competent E. coli 
Samples collected from ligation reactions in method A and B were transformed into 
chemically competent E. coli (DH5α). Following protocol was used for the transformation:  
 
1. Thaw DH5α cells on ice. 
2. Incubate for 10 minutes.  
3. Add 2μl sample (ligation product) to 40μl DH5α cells. 
4. Incubate on ice for 30 minutes. 
5. Heat shock for 30 seconds at 42°C. 
6. Incubate on ice for 2 minutes. 
7. Add 250μl SOC medium. 
8. Incubate at shaker for 60 minutes at 37°C. 
9. Spread sample on pre-warmed LB-plates with correct selection medium.   
10. Incubate overnight at 37°C.   
 
A positive control with pUC19 was made as well as a control with direct transformation of 
undigested vector pFGC-pcoCas9.  
 
DNA Analysis  
Colony PCR for transformed E. coli 
Eleven colonies of transformed E. coli were re-streaked on a LBkanamycin-plate and incubated 
overnight at 37°C. Following incubation, a part of each of the colonies were resuspended in 
20μl dH2O, microwave treated for 5 seconds and used in PCR reactions to amplify the 
genomic region of inserted gRNA120a expression cassettes. Eleven PCR reactions were set 
up as follows: 
 
18 μl mastermix + 0.5 μl NEB_U6_F1 type 1 + 0.5 μl NEB_U6_R2 type 1 + 1 μl resuspended bacteria 
 
The PCR was run according to protocol in figure 9 below.  
 
98°C 98°C    72°C 72°C   
30’’ 10’’  62°C  30’’ 7’  12°C 
   15’’     ∞ 
     × 35    
Figure 9. Illustration of conditions in colony PCR. The figure shows conditions for initial denaturation, the 35 
cycles of denaturation, annealing and extension as well as the final extension. Single apostrophe (’) represent 
minutes and double apostrophes (’’) represent seconds.  
 
PCR samples were in turn electrophoresed on 1% EtBr agarose gel to see product length.  
 
Sequencing of colony PCR products 
Remaining bacteria from two colonies that gave rise to clear bands when its associated colony 
PCR product were electrophoresed on agarose gel, were prepared for sequencing by making 
overnight cultures (37°C) in LB-medium. MiniPreps (Life Technologies) of these overnight 
cultures were made and sent to GATC Biotech for sequencing.  
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Results 
Designed PCR primers  
All primers designed within this project were ordered from Invitrogen (Life Technologies). 
Names and sequences for all primes are listed in appendix A table 1.  
 
Assembly of gRNA  
PCR products showed straight and clear bands when electrophoresed on agarose gel, figure 
10. Obtained product concentrations of assembled gRNA expression cassettes varied between 
19.6 and 93.8 ng/μl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Assembled sgRNA expression cassettes when viewed under UV-light (after being electrophoresed on 
agarose gel). From left to right: 100 bp DNA ladder and 1 kb DNA. These two ladders are followed by two 
gRNA expression cassettes for each of the genes A120 (b), A130 (b), A132 (b), A140, A150 and A160. 
 
Ligation and transformation  
Products that were gel-purified and used in the ligation method A can be seen in figure 11. 
Method A and transformation of associated ligation product into E. coli did not result in 
colony growth. Colonies were seen for the positive control (pUC19) transformed at same 
occasion. Ligation method B on the other hand and transformation of this ligation product 
(vector for Cas9 expression ligated with the gRNA120a expression cassette), resulted in 
colony growth. Digested vector sample that was used in this method can be seen in figure 12. 
Colony PCR were made on an E. coli colony generated from ligation method B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Digestion products from enzyme reactions with EcoRI and XbaI when viewed under UV-light (after 
being electrophoresed on agarose gel). From left to right: 1 kb DNA ladder, 50 bp DNA ladder, digested sample 
of gRNA120a expression cassette and digested vector pFGC-pcoCas9.  
500 bp 
20000 bp 
500 bp 
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Figure 12. Undigested and digested plasmid Maxiprep samples of vector pFGC-pcoCas9 when viewed under 
UV-light (after being electrophoresed on agarose gel). From left to right: 1 kb DNA ladder, digested sample of 
Maxiprep i.e. vector pFGC-pcoCas9 cleaved with EcoRI and XbaI and an undigested vector sample.  
 
Sequencing  
The sequencing of the plasmid in the E. coli colony is shown in figures 13a-d on following 
pages, named GATC_120a.seq. Figure 13a shows an overview of the whole region that was 
sequenced. The forward and reverse primers used to ligate the gRNA120a expression cassette 
into vector pFGC-pcoCas9, NEB_U6_F1 type 1 and NEB_U6_R2 type 1, are illustrated in 
the same figure. The CRISPR site for gene A120 can also be seen. Further, vector pUC119-
gRNA containing the template gRNA is also illustrated in the figure as well as an extraction 
of vector pFGC-pcoCas9.  
 
Figure 13b-d shows enlargements of three parts of figure 13a. Starting with figure 13b, this 
figure illustrates the CRISPR site found in Geneous for A120 and following PAM-sequence. 
The complete sequence is in the desired form of 5’ -G N19 NGG- 3’, seen in the figure by 
GCCGGGGAAGGCCCTGGATTTGG. Moreover in figure 13b, the vector sequence for 
pUC119-gRNA (unspecific gRNA) can be seen as well as part of the sequenced plasmid 
(GATC_120a.seq). The alignment of the three sequences shows that the sequenced E. coli 
colony has a sequence that is a perfect match of the desired CRISPR site rather than a 
sequence that matches the unspecific gRNA within the vector.   
 
Figure 13c illustrates the binding region of the forward primer. In the figure, it can be seen 
that the forward primer sequence matches the plasmid sequence as well as the sequence for 
vector pUC119-gRNA at 14 bases upstream in the primer direction (right). In figure 13d on 
the other hand, the binding region of the reverse primer is illustrated. In this figure, a 
sequence extraction for vector pFGC-pcoCas9 is inserted. Looking at this sequence and also 
the sequence for vector pUC119-gRNA, there is a perfect match of three bases in position 
848-850. Before this point, the E.coli sequence matches the vector pUC119-sequence. After 
this point, there is a match between the E. coli sequence and the extraction for the pFGC-
pcoCas9 vector. Position 848-850 is located within the binding region of the reverse primer, 
indicating that the reverse primer ligates the ends of the gRNA120a expression cassette and 
vector pFGC-pcoCas9.  
 
 
 20000 bp 
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Figure 13a. An overview of a sequenced region within E. coli, in which vector pFGC-pcoCas9 including a gRNA120 expression cassette has been inserted.  The forward and 
reverse primers used to ligate the gRNA120a expression cassette into vector pFGC-pcoCas9, NEB_U6_F1 type 1 and NEB_U6_R2 type 1 are shown as well as the CRISPR 
site for gene A120. Vector pUC119-gRNA containing the template gRNA and an extraction of vector pFGC-pcoCas9 can also be seen in the alignment.  
 
 
 
 
Figure 13b. Enlargement of figure 13a. The CRISPR site found in Geneous for gene A120 and following PAM-sequence is illustrated as A120 – CRISPR site. A sequenced 
region within E. coli, in which vector pFGC-pcoCas9 including a gRNA120 expression cassette has been inserted is shown as well as the pUC119-vector sequence.    
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Figure 13c. Enlargement of figure 13a. The binding region of the forward primer is illustrated as well as the sequenced E. coli. pUC119-gRNA vector sequence is also 
illustrated.  
 
 
 
 
Figure 13d. Enlargement of figure 13a. The binding region of the reverse primer is illustrated as well as the sequenced E. coli. pUC119-gRNA vector sequence is also 
illustrated. Moreover, a sequence extraction for vector pFGC-pcoCas9 can be seen.  
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Discussion 
The aim of this laboratory work was to transform a vector that express Cas9 for plants 
as well as a gRNA sequence targeting gene A120 into a chemically competent strain 
of E. coli cells. This aim has been achieved as the GATC sequencing result of a 
transformed E. coli colony matches the sequence of the CRISPR site for A120, figure 
13b. Another aim was to design primers for additional five previously mentioned 
Arabidopsis genes (figure 4). These primers should be possible to use for assembling 
and ligation of both single and multiple gRNA expression cassettes into vector pFGC-
pcoCas9. This has been done as well, appendix A table 1. However, more can be said 
and discussed about the method and the obtained results.  
 
Starting with the designed primers to work with the PCR method used to assemble 
gRNA expression cassettes, all primers generated gRNA expression cassettes despite 
variations in concentration. The generated products had predicted sizes when checked 
on agarose gel (figure 10) indicating that the generated products are complete gRNA 
expression cassettes. It can thereby be concluded that these primers were correctly 
designed and that the PCR method published by Li et al. (2013) to assemble gRNA 
expression cassettes has a high usability and generates desired products.  
 
Comparing the ligation methods, it appears that method B works while method A 
does not. This statement assumes that the absence of E. coli colonies on LB-plates 
after transformation of ligation products from method A is a result of a failure within 
the ligation method itself rather than any other factor. This is further supported by the 
fact that colony growth was seen for the positive control in the same transformation 
trials. However, a major difference between ligation method A and B that cannot be 
neglected is the concentration of the plasmid (pFGC-pcoCas9) samples used in the 
ligation reactions.  
 
In method A, ligation reactions were set up with Mimiprep plasmid samples with a 
concentration of 122.4 ng/μl. In method B on the contrary, a Maxiprep plasmid 
sample with a concentration of 2 μg/μl was used. This concentration difference can 
also be seen when comparing digested vector samples in figure 11 and 12. The 
brighter band in figure 12 indicates that there is a much higher concentration of 
digested vector compared to the lighter band in figure 11. The concentration 
difference was not compensated by an equivalent difference in sample volumes used 
in the reactions, whereby the plasmid concentration was higher in method B. A low 
plasmid concentration may therefore be the reason why ligation method A did not 
work while method B did. Moreover, factors such as number of bases overlapping in 
the ligation reaction or details such as exclusion of heat inactivation of the enzyme 
digestion reaction in method A may explain why this method did not work.  
 
Leaving the reasoning of why ligation method A did not work and instead focusing on 
the method B that did work, this method successfully generated colony growth of E. 
coli after transformation. Repeats of the same method but with other gRNA 
expression cassettes targeting different genes are thereby expected to generate colony 
growth as well. There is although a risk when working with ligation that fragments 
expected to be ligated together, in fact, are not. In this case, the gel purification of the 
digested vector allowed for removal of undigested vector. However, the risk remained 
that a fragment of undigested vector may have been kept, transformed into E. coli and 
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causing colony growth. Making colony PCR and sample sequencing was thereby 
required in order to show that the sample transformed into E. coli was a pFGC-
pcoCas9 vector having inserted gRNA120a expression cassette rather than being an 
undigested vector sample. Figure 13b proves, as previously mentioned, that the 
plasmid carrying the gRNA120a expression cassette was successfully integrated in E. 
coli.  
 
The sequencing of the plasmid in the E. coli colony does further, apart from showing 
that gRNA120a has been successfully integrated, also show that the ligation of pFGC-
pcoCas9 and the gRNA120a sequence occurs within the binding region of the 
primers, figure 13d. This was expected as primer NEB_U6_R2 type 1 was designed to 
have a sequence matching both the flanking region of the gRNA expression cassette 
and the vector. However, it is always good to prove it. There is no extraction of the 
Cas9-sequence in figure 13c, making it harder to prove that the GATC sequence is a 
ligation result from the gRNA expression cassette and the vector for Cas9 plant 
expression. Although, seeing in figure 13c that the primer sequence matches the 
gRNA expression cassette sequence at a region where the gRNA-vector sequence 
does not match, generates an acceptable prof of a successful ligation within the 
binding region of the primer. Especially since it is known that the forward primer, just 
as the reverse primer, is designed to have a sequence matching the flanking region of 
the gRNA expression cassette as well as the vector for Cas9.  
 
Returning to the topic of primer design, nothing has been discussed when it comes to 
primers created to insert multiple gRNA expression cassettes into a single vector. 
These primers can only be assumed to work as no trials have been made to prove it. 
As ligation method A did not work for insertion of a single gRNA expression cassette, 
this method will neither work for insertion of multiple gRNA expression cassettes. 
The primers may therefor work theoretically, but most likely not in reality. As ligation 
method B with the NEB cloning kit worked, this method should preferably be used in 
future experiments aiming to make insertions of multiple gRNA sequences into vector 
pFGC-pcoCas9. A conclusion of whether or not designed primers work can be 
reached after such trial. 
 
Transformation of vector pFGC-pcoCas9 with the inserted gRNA120a expression 
cassette into Agrobacterium is the next step to continue the work that has been started 
in this project. Once having growing colonies of Agrobacterium, these will be 
transformed into Arabidopsis by using the floral dip method (Clough & Bent, 1998). 
The gRNA will bind to the target site in A120 and induce a DBS. As the cell repairs 
the broken DNA strands by NHEJ (repair by HR is unlikely to occur as no DNA 
template is inserted), there will be deletion of nucleotide(s). This will generate a 
mutation within the plant’s genome that is heritable. Moreover, making the same 
transformation into Arabidopsis for a vector that contains multiple gRNA expression 
cassettes is expected to induce multiple DSBs and thereby generate progenies that are 
complete infertile.  
 
Continuing the started work in this project will not only allow for study of genes 
involved in stamen development of Arabidopsis. Working with the CRISPR Cas9 
method will make it possible to investigate aspects such as its mutation efficiency and 
off-target frequency; aspects that preferably should be further investigated to better 
understand and discuss pros and cons with the CRISPR Cas9 method. It would also be 
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valuable to make experiments to e.g. investigate whether CRISPR Cas9-induced 
mutations can be tissue specific and make a gene expressed in one part of a plant 
while it is silent in another part. Published research of such experiments has not been 
found within the literature study of this thesis, but is highly interesting when it comes 
to usability of the CRISPR Cas9 technique.  
 
 
Conclusion 
The aim of Part I is achieved as the modified sequence and the vector pFGC-pcoCas9 
was verified in E. coli. Primers created and the method used to assemble a gRNA 
expression cassettes works. The primers and the method can thereby be used in future 
experiments. Following assembly of gRNA, ligation method B should be used to 
ligate an assembled gRNA expression cassette into vector pFGC-pcoCas9. Making 
trials with this ligation method and associated primers are recommended to generate 
vector collections that contain both single and multiple gRNA expression cassettes.  
 
The work that has been started in this project proves that it is easy to design sgRNAs. 
The CRISPR Cas9 method can hence be described as a method with great potential 
that is easy to use, supposing that the continued work of Agrobacterium 
transformation into Arabidopsis is not more complicated than any similar 
transformation with another vector. Using CRISPR Cas9 may in the small perspective 
of this project allow for a deeper understanding of genes involved in stamen 
development of plants. In a greater perspective, knowledge about how CRISPR Cas9 
can be used to generate plants of Arabidopsis that have reduced male fertility can be 
applied to crop plants. Findings from this work can thereby be used to enhance hybrid 
seed production and improve crop yield and quality.  
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Part II 
Background 
The EU legislation for genetically modified organisms (GMOs)  
There is a comprehensive legal framework in place for authorisation, traceability and 
labelling of genetically modified organisms (GMOs) within the European union; 
Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 
September 2003 on genetically modified food and feed (European Parliament, 2003a) 
and Directive 2001/18/EC of the European Parliament and of the Council of 12 March 
2001 on the deliberate release into the environment of genetically modified organisms 
and repealing Council Directive 90/220/EEC (European Parliament, 2001).  
 
For the purpose of Directive 2001/18/EC, following definition is used to describe a 
genetically modified organism (GMO): 
 
“Genetically modified organism (GMO) means an organism, with the exception of 
human beings, in which the genetic material has been altered in a way that does not 
occur naturally by mating and/or natural recombination”.  
 
In the Annex I of Directive 2001/18/EG, techniques that give rise to GMOs, 
techniques that are not considered to result in GMOs and techniques of genetic 
modification that are excluded from the Directive can be found. Techniques that are 
considered to generate GMOs are recombinant nucleic acid techniques as well as 
techniques that involves introduction of heritable material that are created outside the 
organisms. Examples of such methods and materials are micro-injections, macro-
injections and micro-encapsulation. Cell fusion or hybridisation techniques are also 
considered to be techniques that generate GMOs, as there is formation of new 
heritable genetic material that does not occur naturally.  
 
When it comes to techniques that are not considered to give GMOs, three methods are 
listed in Directive 2001/18/EG; in vitro fertilisation, natural processes e.g. 
conjugation, transduction and transformation and finally polyploidy induction. A 
requirement is although that these three listed techniques do not involve use of 
recombinant nucleic acid molecules or any GMOs made from techniques that are not 
excluded from the Directive. Two techniques that are listed to give GMOs but 
excluded from Directive 2001/18/EG are mutagenesis and cell fusion of plants cells.   
 
Cultivation of GMO within the EU territory 
A GMO intended for placing on the market within the EU or to be cultivation within 
the EU territory, has to undergo an individual risk assessment in accordance with 
Regulation (EC) No 1829/2003 and Annex II in Directive 2001/18/EG before it can 
be authorised. The risk assessment includes evaluation on effects on human health 
and the environment with the aim to ensure a high level of protection.   
 
The scientific risk assessment of GMOs is carried out by European Food Safety 
Authority (EFSA) in cooperation with the Member States’ scientific bodies (European 
Commission, 2015). Based on conclusions stated by EFSA regarding potential effects 
on human and animal health and the environment of a particular GMO, the European 
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Commission will make a draft decision for GMO authorisation. Member States of the 
European Union vote on this draft decision within the Standing Committee. A 
qualified majority is needed for a decision to be reached. If there is no qualified 
majority for or against the draft decision at this stage, the draft will be tabled for an 
additional voting in the Appeal Committee. If there is no qualified majority for or 
against the draft decision at this stage either, the Commission has to take a decision 
on authorisation without support of Member States in relevant committees.  
 
When it comes to authorisation of GMOs, there is rarely any qualified majority 
reached within the Standing Committee or the Appeal Committee; most arguments 
opposing the authorisation reflect national concerns rather than scientific 
considerations (European Commission, 2015). The European Council did thereby 
came to the conclusion that improvements were needed in the legal framework of 
GMOs (Council of the European Union, 2008). Directive (EU) 2015/412 has for this 
purpose recently amended article 26 in Directive 2001/18/EG. Directive (EU) 
2015/412 makes it possible for Member States to restrict or prohibit the cultivation of 
GMOs in their territory despite these being authorised for cultivation and placing on 
the market at Union level.  
 
Reasons stated by Member States’ for restricting or preventing cultivating of an 
authorised GM crop should, according to Directive (EU) 2015/412, not affect the 
scientific risk assessment in the system of Union authorisation of GMOs. Member 
States can make their decisions on grounds with respect to environmental policies that 
are clearly distinct from the assessment of health- and environmental impacts 
evaluated in accordance with the authorisation procedure stated in Directive 
2001/18/EC and in Regulation (EC) No 1829/2003. Member States can also make 
decisions on grounds of socioeconomic impacts as well as public policy and cultural 
traditions. However, details of if and how Directive (EU) 2015/412 can be interpreted 
in Swedish legislation for GMOs are unknown.  
 
Detection and identification – the requirement for a policy 
As there is legislation for what techniques that gives GMOs, detection methods to 
trace and identify GMOs has to be available. Detection and detection methods is for 
this purpose defined as a methods that allow determination of the existence of a 
change in the genetic material (Lusser et al., 2011). This can be done by reference to 
an appropriate comparator. Identification of GMOs on the other hand, means that 
detected existence of a genetic change has to be identified as a genetic modification 
caused by a certain technique.  
 
As mentioned in the introduction and in the section above, mutagenesis as a plant 
breeding method is excluded from the EU GMO legislation as there is no detection 
method available that identifies and distinguishes a genetic modification caused by 
mutagenesis from a spontaneous mutation. Detection methods allowing for 
identification of GMOs as such or in products have to be available at all stages of 
GMO placing on the market according to Regulation (EC) No 1829/2003 and 
Regulation (EC) No 1830/2003 (European Parliament, 2003b). Examples of such 
methods are DNA-based analysis, protein-based analysis and metabolite-based 
analysis (Lusser et al., 2011). DNA-bases analysis, particularly DNA amplification-
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based methods, is the most applicable for detection and identification of genetic 
modifications.  
 
DNA amplification-based methods (PCR) 
The most commonly used DNA amplification-based method to amplify specific 
DNA, is PCR technique (Lusser et al., 2011; Miraglia et al., 2004). To detect and 
identify whether or not there is GMO present in a sample, a conventional qualitative 
PCR method can be used (Lusser et al., 2011). A multiplex PCR technique can also 
be used to amplify two or more loci simultaneously (Henegariu et al., 1997). 
However, PCR primers have to be designed, whereby information on the modified 
sequence is required.  
 
If a food sample is to be investigated for presence of GMO, a quantitative PCR 
method is most commonly used (Buh Gašparič et al., 2010; Miraglia et al., 2004). In 
a quantitative real-time PCR, primers as well as fluorescent probes are used. Primers 
will bind to the inserted genomic material (GMO) and the probes will further emit 
fluorescent light that corresponds to the amount of synthesised DNA in the PCR 
(Miraglia et al., 2004). The amount of GMO in the sample can thereby be measured, 
which is relevant as Regulation (EC) No 1830/2003 states that GMO products 
containing more than 0,9 % approved GMO product has to be labelled at all stages of 
placing on the market. Products containing less than 0,9 % approved GMO products 
do not need to be GMO-labelled.  
 
Detecting and identifying GMOs may be possible when having information on the 
modified sequence. This kind of information can for instance be adapted from 
available GMO Detection Databases (Dong et al., 2008), but it inevitably evokes a 
question of whether or not it is possible to detect GMO without this kind of prior 
information. Tengs et al., (2007) has published a microarray-based method for 
detection of unknown genetic modifications. Fragments equal or greater than 140 bp 
can be detected without prior knowledge of the transgene sequence. A differential 
PCR may also be used to detect unauthorised GMO (Cankar et al., 2008). This 
method has been found to work when searching for donor organisms of the 
Cauliflower 35S promoter.    
 
New plant breeding techniques 
In 2007, a working group was established by the European Commission to evaluate 
whether eight new techniques of genetic modification, seven of which can be used to 
alter plant DNA, should fall within the EU GMO legislation (Lusser et al., 2011). All 
seven techniques are listed in table 4 below together with short summaries of intended 
changes/effects when using the techniques and possibilities for detection. The new 
technique of CRISPR Cas9 is also listed in the table.  
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Table 4. Short summary of intended changes/effects and possibilities for detection of 
seven new plant breeding techniques. Information in the table is adapted from (Lusser 
et al., 2011). Intended changes/effects and possibilities for detection is also given for 
the CRISPR Cas9 method.  
Name  Intended changes/effects Possibilities for detection and identification 
 
Zink finger 
nuclease (ZFN) 
technology 
 
ZFN-1: Deletion of one or few 
nucleotides as a result of NHEJ repair of 
an induced DBS. No repair template is 
provided to the cell.  
ZFN-2: Induced mutation through HR 
repaired of a DSB. Template DNA 
homologous to the targeted area, except 
for the desired base pair alteration that 
should be induced, is delivered to the cell 
with the ZFN.  
 
ZFN-3: A constructed recombinant DNA 
molecule (transgene) is delivered to the 
cell with the ZFN. Transgene integration 
by HR repair of DSB.  
 
 
ZFN-1 and ZFN-2: Mutations can be detected 
but not distinguished from natural mutations or 
mutations caused by other mutation techniques.      
 
 
 
 
 
 
 
 
ZFN-3: Mutations can be detected with PCR. 
Identification requires prior knowledge.  
 
 
Oligonucleotide 
directed 
mutagenesis 
(ODM) 
 
 
Site-specific nucleotide substitution. 
Oligonucleotides are homologous to 
target sequence with the exception for 
nucleotide(s) to be modified. These are 
inserted to a cell and target the 
homologous sequence. Substitution 
occurs as the cell repairs the mismatches. 
 
 
Mutations cannot be detected unless there is 
information provided on nucleotides close to 
the mutation-site. Identification is not possible.   
  
 
Cisgenesis and 
intragenesis 
 
Cisgenesis:  DNA-fragment from a plant 
species (from itself or from a cross-
compatible plant species) is inserted. 
Inserted gene includes introns and 
regulatory sequences i.e. the gene is 
unchanged.  
 
Intragenesis: DNA-fragment from a plant 
species (from itself or from a cross-
compatible plant species) is inserted. The 
inserted DNA is a new combination of 
DNA fragments.  
 
 
Detection and identification is possible if 
information regarding mutation site is known 
(PCR). Searching for mutations without 
information provided (e.g. through genome 
sequencing) has not been proved to both detect 
and identify technique-induced mutations.   
 
 
RNA-dependent 
DNA 
methylation 
(RdDM) 
 
 
Genes encoding RNAs, homologous to 
plant sequences, are inserted in plant 
cells. These genes generate small double 
stranded RNAs that induce methylation 
and thereby inhibit transcription of the 
homologous sequence.  
 
 
Detection and identification is not possible no 
matter if prior information given or not.  
 
Grafting (on 
GM rootstock) 
 
A chimeric organism is created through 
attachment of vegetative component 
(non-GM) above ground to a rootstock of 
another plant (GM).  
 
 
Detection and identification is not possible as 
the DNA sequence of the non-GM scion is not 
modified.  
 
 
Reverse 
breeding 
 
A homozygous parental line is generated 
from double-haploid (DH) plants. This 
requires suppression of meiotic 
crossovers as well as fixation of non-
recombinant chromosomes in DH.  
 
Detection and identification is not possible as 
the product cannot be distinguished from a 
product produced from conventional breeding.  
 
 34 
 
Agro-infiltration 
(agro-infiltration 
“sensu stricto”, 
agro 
inoculation, 
floral dip) 
 
 
Agro-infiltration “sensu stricto” and agro 
inoculation: Temporary expression of 
specific coding sequence. This is done 
without integration of introduced DNA in 
the plant genome.  
 
Floral dip: Seedlings are stably 
transformed. No need for plant 
regeneration phase. Properties of a 
transgenic plant are obtained.  
 
 
Agro-infiltration: Detection and identification is 
only possible in agro-infiltrated plants. 
Detection and identification is not possible in 
the products of these plants unless the inserted 
fragment is stable.   
 
Floral dip: Detection and identification is 
possible through PCR. Unless no information is 
available, identification is not possible.  
 
 
CRISPR 
(clustered 
regularly 
interspaced 
short 
palindromic 
repeat) Cas9 
 
 
Site-specific mutation(s) are induced in 
the NHEJ repair process of an 
endogenous DSB. Deletions of  
 
CRISPR Cas9 will cause similar genetic 
mutations as ZFN-1 and ZFN-2. Mutations can 
be detected but not distinguished from natural 
mutations or mutations caused by other 
mutation techniques. 
 
ZFN-3, cisgenesis and intragenesis as well as agro-infiltration (floral dip) are the only 
methods out of all seven plant breeding techniques where it is possible to detect and 
identify the products (Lusser et al., 2011). This does however require prior 
information about the introduced modification.   
 
Field trials with CRISPR Cas9-generated plant mutants in Sweden 
Swedish legislation for GMOs is stated in Miljöbalken (MB) 1998:808 
(Regeringskansliet/Lagrummet, 2015b). When it comes to field trials with plants bred 
with techniques that are classified as GM-techniques (Directive 2001/18/EG), 
permission has to be received before such trials can be performed according to MB 
13:12 and the Swedish constitution (FU) 2002:1086 (Regeringskansliet/Lagrummet, 
2015a). Application for field trials should be sent to the Swedish Board of 
Agriculture. Information to be included in the application is regulated by FU 2:2-6. 
However, FU 4 § p. 2 states that crops bred with mutagenesis or cell fusion i.e. 
techniques listed as excluded from legislation within Directive 2001/18/EG are not 
regulated by MB 13.  
 
As mentioned in the introduction of this report, the EU is still undecided as to whether 
all, some or any of the new plant breeding techniques should be subject to the 
traditional GMO legislation. Considering this in the context of field trials with GMO 
in Sweden, no information is available on whether or not an application has to be sent 
in and approved before field trials with plants bred with any of these new techniques 
can be performed. Relating this to Part I of this report, it remains unknown what rules 
to follow for future field trials with the Arabidopsis-plants having site-specific 
mutations induced by CRISPR Cas9. In order to seek answer, a formal letter has been 
sent to the Swedish Board of Agriculture. The letter can be found in Appendix B. No 
English translation is available, but the questions asked are:  
 
1. Are plants, in which mutations are induced by use of CRISPR Cas9, subjected 
to the EU GMO legislation? 
2. Are there any authorisation requirements for making field trials with these 
plants? 
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3. Are there any regulations to be followed when making the field trials? If such 
are missing, is it still possible to perform field trials? 
 
The letter was sent to the Board of Agriculture in June 2015. In the same period of 
time, a letter from the European Commission was sent to all competent authorities for 
Directive 2001/18/EC. In this letter, it is written that some Member States within the 
EU has given permission for field trials with oilseed rape produced with ODM i.e. 
one of the new plant breeding techniques that is being legally evaluated. The 
European Commission is further asking the Member States to await a legal 
interpretation before authorising any products produced with the new plant breeding 
techniques. Finally, it is written that a legal analysis will be presented before the end 
of 2015. The letter sent from the European Commission can be found in appendix D.  
 
 
Results and Discussion 
Regulation (EC) No 1829/2003 and Directive 2001/18/EG make a legal framework 
for GMOs within the EU and regulates cultivation of crops bred with techniques that 
alter the genetic material in a way that does not occur naturally. Comparing a crop 
regarded as a GMO to a crop being conventionally bred, there is an induced genetic 
modification within the genome of the GMO that can be detected, identified and 
distinguished from a spontaneous mutation. In crops conventionally bred, induced 
mutations are indistinguishable from such mutations.  
 
The reason for having legislation for GMOs is to protect humans, animals and the 
environment from potential cumulative long-term effects that may arise after an 
intended release of GMO on the market. An example of such long-term effect could 
be an uncontrolled reproduction and survival of the genetically modified organism 
that may disturb the natural ecosystem. The legislation does also serve the purpose of 
taking ethical aspects into consideration before releasing GMOs.  
 
Since Directive 2001/18/EG was agreed on, new plant breeding techniques have 
evolved. Despite the European Commissions’ establishment of a working group to 
evaluate whether these new techniques should fall within the scope of the EU GMO 
legislation, no recommendation has been issued. The legal outcome of these new 
plant breeding techniques is therefore unknown. One reason behind this unsatisfying 
situation is the fact that the new plant breeding techniques generate products that 
cannot be distinguished from spontaneous mutations or mutations induced by any of 
the two techniques listed in Annex I B as excluded from Directive 2001/18/EG. Only 
ZFN-3, cisgenesis, intragenesis and agro-infiltration (floral dip) can be detected and 
identified. The new plant breeding techniques seem to fall within the EU legislation in 
that they involve modification of genetic material in a way that does not naturally 
occur, but they offer problems for the legislators in that the changes to the genome 
created are untraceable. If crops bred using these techniques should be classified as 
GMOs, it therefore follows that the current legislation requires considerable 
amendment and reworking.  
 
As previously mentioned, the intention of the law is to protect humans, animals and 
the environment from unknown effects of GMOs. This aim is further supported by the 
Directive (EU) 2015/412 that allows Member States of the European Union to restrict 
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or prohibit the cultivation of GMO crops with regards to environmental factors. 
Subjecting the new plant breeding techniques to the EU GMO legislation puts the 
legislation into action. The new plant breeding techniques, as previously mentioned, 
induce mutations similar to mutations that naturally occur in all living organisms; 
subsequently plants produced with the new techniques cannot in a convincing way be 
argued to have any more unknown effects than other wild-type plants. Subjecting the 
new plant breeding techniques to the current EU GMO legislation means that an 
organism classified as GMO is in theory identical to a wild-type organism - where 
mutations have occurred through evolution. Consequently the GMO cannot be argued 
to have a higher competitiveness than the wild-type organism and as such the GMO in 
turn cannot be said to disturb the ecosystem more than any other organism. 
 
It is my belief that there is a risk of plant breeding innovations being prevented if the 
new techniques including CRISPR Cas9 are placed under the scope of the EU GMO 
legislation. Applications for field trials for GMOs are expensive, especially as new 
cultivars cannot be used within the EU territory, which reduces the number of trials 
performed. I thereby propose that the European Commission, if the new plant 
breeding techniques are to be included in Directive 2001/18/EG, list these in Annex I 
B. Although, another important aspect that deserves attention in this context, is 
whether there is a need of the whole legislation i.e. Directive 2001/18/EG to be 
rewritten. Considering there is a continuous development of new techniques in plant 
breeding; the CRISPR Cas9 method is merely one example of a technique that has 
evolved since the Commission started working with the area in 2007, there would be a 
potential gain in making the legislation product-based rather than based on 
techniques. GMOs could, for this purpose, be defined by all traits displayed after 
induced genetic modification rather than by technique used.  
 
Having a product-based GMO law would, in my opinion, to a greater extent make 
sense in context of the aim of the legislation. Release of organisms that are genetically 
modified to such extent that they have negative effects on human and animal health 
should be prevented by legislation. These organisms would also be prevented by 
legislation if they can reproduce out of human control and express a higher 
competitiveness in environments that they are not intended for, as this would risk 
disturbing the natural ecosystem. Organisms that are not a risk for human and animal 
health and/or do not have a beneficial competitiveness, should be seen as similar to 
wild type organisms and thereby not be prevented by the law. This decision should be 
made with regards to the organism itself and its features rather than by technique used 
to produce it. A product-based legislation would also make it easier to handle new 
techniques for genome editing that may evolve in the future. No amendments of the 
law are needed as the techniques themselves are not to be subjected to it.  
 
Despite my analysis of the EU GMO legislation and how the new plant breeding 
techniques should be considered in its context, the question remains whether or not an 
application has to be sent in and approved before making field trials with Arabidopsis 
mutated by use of CRISPR Cas9. Considering the letter sent from the European 
Commission and its demands to Member States to await the legal outcome before 
approving any field trials with the new plant breeding techniques, it is understandable 
why I have not received any answer to the questions that I sent. The Swedish Board of 
Agriculture has however asked for complementary information. This is interpreted as 
a first step in the procedure of preparing a reply. The letter with complementary 
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information can be found in appendix C. Meanwhile, it is clear that the delay in 
decisions on this matter by European policy makers not only hinders applied research 
and technology development but also directly influence curiosity driven- or basic 
science in a negative manner. 
 
 
Conclusion 
Techniques that induce genetic modifications of organisms in a way that do not occur 
naturally by mating and/or natural recombination are listed in Directive 2001/18/EG. 
Products derived from these techniques, GMOs, are subjected to Regulation (EC) No 
1829/2003. The EU GMO legislation can thereby be described to regulate GMO 
products on the basis of what techniques that have been used to generate these rather 
than considering the genetic modification induces as such. In turn, having a 
legislation being based on techniques requires considerable amendment and 
reworking for any new technique that may evolve. The EU GMO legislation is 
thereby proposed a change so as to regulate GMOs on basis of all traits displayed 
after induced genetic modification rather than by the technique used.   
 
Making the EU GMO legislation product-based would make it easier to decide 
whether new plant techniques should fall under the scope of the legislation. This 
would, as an example, reduce the uncertainties regarding whether or not an 
application has to be approved before making field trials with plans being mutated by 
use of the CRISPR Cas9 method. Reducing uncertainties for the EU GMO legislation 
will likely enhance the development of new techniques and thereby contribute to great 
innovations with the area of plant breeding. 
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Appendix Table 1. Primers used.  
Oligo Name Sequence (5' to 3') 
gRNA_A_rev GTGTCTCAGGGAGTACTAC 
gRNA_B_fwd AGTAGTACTCCCTGAGAC 
gRNA_B_rev GCCTCCTAAACTGTGAAG 
gRNA_C_fwd TTCTTCACAGTTTAGGAGG 
gRNA_C_rev GTCCAAATTTTTCCATGGC 
gRNA_D_fwd TGCCATGGAAAAATTTGGAC 
gRNA_D_rev GTCTCTTTTCCTTGCCCTAATAATG 
gRNA_E_fwd TTAGGGCAAGGAAAAGAG 
NEB_U6_F1 type 1 CTGATTTGAAAAATCTCAGGCGGAATTCAGAAATCTC 
NEB_U6_R2 type 1 GATATCGGCGCGCCTGCGTCTAGATAATGCCAAC 
U6_F1 NEB_B AGTAGTACTCCCTGAGACACAGAAATCTCAAAATTCCG 
U6_F1 NEB_C TTCTTCACAGTTTAGGAGGCAGAAATCTCAAAATTCCG 
U6_F1 NEB_D TGCCATGGAAAAATTTGGACAGAAATCTCAAAATTCCG 
U6_F1 NEB_E TTAGGGCAAGGAAAAGAGACAGAAATCTCAAAATTCCG 
U6_F1 type1 GCGGAATTCAGAAATCTCAAAATTCCG 
U6_F1 type2 GCGTCTAGAAGAAATCTCAAAATTCCG 
U6_F2 120a GCCGGGGAAGGCCCTGGATTTGGGTTTTAGAGCTAGAAATAGC 
U6_F2 120b GCTGAAGCATGCATCGTCAAGAGGGTTTTAGAGCTAGAAATAGC 
U6_F2 130a GGATACGGCCGTGGCCACAATGGGTTTTAGAGCTAGAAATAGC 
U6_F2 130b GACCAAGGATGATCGCTTCATGGGTTTTAGAGCTAGAAATAGC 
U6_F2 132a GATCACTTGGGAATAGGTAGTGGGTTTTAGAGCTAGAAATAGC 
U6_F2 132b GGGCCGGACCCAGATTCTGGCGGGTTTTAGAGCTAGAAATAGC 
U6_F2 135 GTATTCCTACAGGAAGATTCGGGGTTTTAGAGCTAGAAATAGC 
U6_F2 140 GACTTAGGAAAAGTTTTTGAAGGGTTTTAGAGCTAGAAATAGC 
U6_F2 150 GGGAAGACAGATAGTACTCCCGGGTTTTAGAGCTAGAAATAGC 
U6_F2 160 GGGGTCTACATTGTCTACATGGGGTTTTAGAGCTAGAAATAGC 
U6_R1 120a CCAAATCCAGGGCCTTCCCCGGCAATCACTACTTCGTCTCT 
U6_R1 120b CCTCTTGACGATGCATGCTTCAGCAATCACTACTTCGTCTCT 
U6_R1 130a CCATTGTGGCCACGGCCGTATCCAATCACTACTTCGTCTCT 
U6_R1 130b CCATGAAGCGATCATCCTTGGTCAATCACTACTTCGTCTCT 
U6_R1 132a CCACTACCTATTCCCAAGTGATCAATCACTACTTCGTCTCT 
U6_R1 132b CCGCCAGAATCTGGGTCCGGCCCAATCACTACTTCGTCTCT 
U6_R1 135 CCCGAATCTTCCTGTAGGAATACAATCACTACTTCGTCTCT 
U6_R1 140 CCTTCAAAAACTTTTCCTAAGTCAATCACTACTTCGTCTCT 
U6_R1 150 CCGGGAGTACTATCTGTCTTCCCAATCACTACTTCGTCTCT 
U6_R1 160 CCCATGTAGACAATGTAGACCCCAATCACTACTTCGTCTCT 
U6_R2 type1 GCGTCTAGATAATGCCAACTTTGTACA 
U6_R2 type2 GCGGCGATCGCTAATGCCAACTTTGTACA 
U6_R2_NEB_A GTGTCTCAGGGAGTACTACTTAATGCCAACTTTGTACA 
U6_R2_NEB_B GCCTCCTAAACTGTGAAGAATAATGCCAACTTTGTACA 
U6_R2_NEB_C GTCCAAATTTTTCCATGGCATAATGCCAACTTTGTACA 
U6_R2_NEB_D GTCTCTTTTCCTTGCCCTAATAATGCCAACTTTGTACA 
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